Daniel Martín-Pérez

Daniel Martín-Pérez

Auto-generated profile, based on publicly available information

Daniel Martín-Pérez

Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2014 in Nature
Verified
Journal Article
Closed access
LALORENA ARRANZ
LORENA ARRANZ
ASAbel Sánchez-Aguilera
Abel Sánchez-Aguilera
DMDaniel Martín-Pérez
Daniel Martín-Pérez
JIJoan Isern
Joan Isern
XLXavier Langa
Xavier Langa
SMSimón Méndez-Ferrer
Simón Méndez-Ferrer

25 September 2014 in eLife
Verified
Journal Article
Open access
JIJoan Isern
Joan Isern
AGAndrés García-García
Andrés García-García
AMAna M Martín
Ana M Martín
LALORENA ARRANZ
LORENA ARRANZ
DMDaniel Martín-Pérez
Daniel Martín-Pérez
SMSimón Méndez-Ferrer
Simón Méndez-Ferrer
Mesenchymal stem cells (MSCs) and osteolineage cells contribute to the hematopoietic stem cell (HSC) niche in the bone marrow of long bones. However, their developmental relationships remain unclear. In this study, we demonstrate that different MSC populations in the developing marrow of long bones have distinct functions. Proliferative mesoderm-derived nestin− MSCs participate in fetal skeletogenesis and lose MSC activity soon after birth. In contrast, quiescent neural crest-derived nestin+ cells preserve MSC activity, but do not generate fetal chondrocytes. Instead, they differentiate into HSC niche-forming MSCs, helping to establish the HSC niche by secreting Cxcl12. Perineural migration of these cells to the bone marrow requires the ErbB3 receptor. The neonatal Nestin-GFP+ Pdgfrα− cell population also contains Schwann cell precursors, but does not comprise mature Schwann cells. Thus, in the developing bone marrow HSC niche-forming MSCs share a common origin with sympathetic peripheral neurons and glial cells, and ontogenically distinct MSCs have non-overlapping functions in endochondrogenesis and HSC niche formation.

1 December 2014 in Cell Stem Cell
Verified
Journal Article
Closed access
ASAbel Sánchez-Aguilera
Abel Sánchez-Aguilera
LALORENA ARRANZ
LORENA ARRANZ
DMDaniel Martín-Pérez
Daniel Martín-Pérez
AGAndrés García-García
Andrés García-García
VSVaia Stavropoulou
Vaia Stavropoulou
SMSimón Méndez-Ferrer
Simón Méndez-Ferrer

1 May 2013 in Cell Reports
Verified
Journal Article
Open access
JIJoan Isern
Joan Isern
Beatriz Martín-AntonioBeatriz Martín-Antonio
Beatriz Martín-Antonio
RGRoshanak Ghazanfari
Roshanak Ghazanfari
AMAna M. Martín
Ana M. Martín
JLJuan Antonio Lopez
Juan Antonio Lopez
SMSimón Méndez-Ferrer
Simón Méndez-Ferrer
Strategies for expanding hematopoietic stem cells (HSCs) include coculture with cells that recapitulate their natural microenvironment, such as bone marrow stromal stem/progenitor cells (BMSCs). Plastic-adherent BMSCs may be insufficient to preserve primitive HSCs. Here, we describe a method of isolating and culturing human BMSCs as nonadherent mesenchymal spheres. Human mesenspheres were derived from CD45- CD31- CD71- CD146+ CD105+ nestin+ cells but could also be simply grown from fetal and adult BM CD45--enriched cells. Human mesenspheres robustly differentiated into mesenchymal lineages. In culture conditions where they displayed a relatively undifferentiated phenotype, with decreased adherence to plastic and increased self-renewal, they promoted enhanced expansion of cord blood CD34+ cells through secreted soluble factors. Expanded HSCs were serially transplantable in immunodeficient mice and significantly increased long-term human hematopoietic engraftment. These results pave the way for culture techniques that preserve the self-renewal of human BMSCs and their ability to support functional HSCs.

17 January 2019 in Blood
Verified
Journal Article
Closed access
PDF file
AGAndrés García-García
Andrés García-García
CKClaudia Korn
Claudia Korn
MGMaría García-Fernández
María García-Fernández
ODOlivia Domingues
Olivia Domingues
JVJavier Villadiego
Javier Villadiego
SMSimón Méndez-Ferrer
Simón Méndez-Ferrer
Hematopoietic stem and progenitor cells (HSPCs) and leukocytes circulate between the bone marrow (BM) and peripheral blood following circadian oscillations. Autonomic sympathetic noradrenergic signals have been shown to regulate HSPC and leukocyte trafficking, but the role of the cholinergic branch has remained unexplored. We have investigated the role of the cholinergic nervous system in the regulation of day/night traffic of HSPCs and leukocytes in mice. We show here that the autonomic cholinergic nervous system (including parasympathetic and sympathetic) dually regulates daily migration of HSPCs and leukocytes. At night, central parasympathetic cholinergic signals dampen sympathetic noradrenergic tone and decrease BM egress of HSPCs and leukocytes. However, at daytime, de-repressed sympathetic noradrenergic activity causes predominant BM egress of HSPCs and leukocytes via β3-AR. This egress is locally supported by light-triggered sympathetic cholinergic activity, which inhibits BM vascular cell adhesion and homing. In summary, central (parasympathetic) and local (sympathetic) cholinergic signals regulate day/night oscillations of circulating HSPCs and leukocytes. This study shows how both branches of the autonomic nervous system cooperate to orchestrate daily traffic of HSPCs and leukocytes. Key points Central parasympathetic signals repress sympathetic tone at night to orchestrate day/night HSPC traffic. Local sympathetic cholinergic signals modulate HSPC traffic by inhibiting diurnal BM vascular adhesion and β3-adrenergic signaling at night.

4 February 2010 in Haematologica
Verified
Journal Article
Closed access
MWM. B. Wozniak
M. B. Wozniak
RVR. Villuendas
R. Villuendas
JBJ. R. Bischoff
J. R. Bischoff
CBCarmen Blanco-Aparicio
Carmen Blanco-Aparicio
MFMartinez-Leal Juan Fernando
Martinez-Leal Juan Fernando
POP. L. Ortiz-Romero
P. L. Ortiz-Romero
Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma. In spite of emerging information on the effect of vorinostat in many types of cancer, little is yet known about this drug's mechanism of action, which is essential for its proper use in combination therapy. We investigated alterations in gene expression profile over time in cutaneous T-cell lymphoma cells treated with vorinostat. Subsequently, we evaluated inhibitors of PI3K, PIM and HSP90 as potential combination agents in the treatment of cutaneous T-cell lymphoma. The genes significantly up- or down-regulated by vorinostat over different time periods (2-fold change, false discovery rate corrected P value<0.05) were selected using the short-time series expression miner. Cell viability was assessed in vitro in cutaneous T-cell lymphoma cells through measuring intracellular ATP content. Drug interactions were analyzed by the combination index method with CalcuSyn software. The functional analysis suggests that vorinostat modifies signaling of T-cell receptor, MAPK, and JAK-STAT pathways. The phosphorylation studies of ZAP70 (Tyr319, Tyr493) and its downstream target AKT (Ser473) revealed that vorinostat inhibits phosphorylation of these kinases. With regards to effects on cutaneous T-cell lymphoma cells, combining vorinostat with PI3K inhibitors resulted in synergy while cytotoxic antagonism was observed when vorinostat was combined with HSP90 inhibitor. These results demonstrate the potential targets of vorinostat, underlining the importance of T-cell receptor signaling inhibition following vorinostat treatment. Additionally, we showed that combination therapies involving histone deacetylase inhibitors and inhibitors of PI3K are potentially efficacious for the treatment of cutaneous T-cell lymphoma.